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Background: Individual response to medications varies significantly among different populations, and great
progress in understanding the molecular basis of drug action has been made in the past 50 years. The field of
pharmacogenomics seeks to elucidate inherited differences in drug disposition and effects. While we know that
different populations and ethnic groups are genetically heterogeneous, we have not found any pharmacogenomics
information regarding minority groups, such as the Tajik ethnic group in northwest China.
Results: We genotyped 85 Very Important Pharmacogene (VIP) variants selected from PharmGKB in 100 unrelated,
healthy Tajiks from the Xinjiang Uygur Autonomous Region and compared our data with HapMap data from four
major populations around the world: Han Chinese (CHB), Japanese in Tokyo (JPT), Utah Residents with Northern
and Western European Ancestry (CEU), and Yorubia in Ibadan, Nigeria (YRI). We found that Tajiks differed from CHB,
JPT and YRI in 30, 32, and 32 of the selected VIP genotypes respectively (p < 0.005), while differences between Tajiks
and CEU were found in only 6 of the genotypes (p < 0.005). Haplotype analysis also demonstrated differences
between the Tajiks and the other four populations.
Conclusion: Our results contribute to the pharmacogenomics database of the Tajik ethnic group and provide a
theoretical basis for safer drug administration that may be useful for diagnosing and treating disease in this population.
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To date, pharmacogenomic studies have focused on can-
didate genes involved in drug pharmacokinetics or
pharmacodynamics. Many of these genes contain func-
tional polymorphisms that are obvious pharmacological
choices for investigation in appropriate clinical popula-
tions [1,2]. For some drugs, genetic information is im-
portant to avoid drug toxicity and to optimize response
[2,3]. Pharmacogenomic studies are rapidly elucidating
the inherited nature of differences in drug disposition
and effects, thereby enhancing drug discovery and pro-
viding a stronger scientific basis for optimizing drug
therapy on an individual basis [4].* Correspondence: cchen898@nwu.edu.cn
1School of Life Sciences, Northwest University, Mailbox 386, #229 North
Taibai Road, Xi’an 710069, Shaanxi, China
2National Engineering Research Center for Miniaturized Detection Systems,
Xi’an 710069, China
Full list of author information is available at the end of the article
© 2014 Zhang et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Tajiks are an ethnic group with a worldwide population of
15 to 20 million; they live mostly in Tajikistan, Afghanistan,
Uzbekistan, and the Xinjiang Uygur Autonomous Region
[4]. According to the 2010 census, approximately
51,000 Tajiks live in China, mostly in the Tashkurgan
Tajik Autonomous County, which is located in the east-
ern part of the Pamir Plateau.
The Pharmacogenetics and Pharmacogenomics Know-
ledge Base (PharmGKB: http://www.pharmgkb.org) is
devoted to disseminating primary data and knowledge in
pharmacogenetics and pharmacogenomics and has an-
notated genes that are important for drug response. This
information is presented in the form of Very Important
Pharmacogene (VIP) summaries, pathway diagrams, and
curated literature [5]. It currently contains information
for more than 3000 drugs, 3000 diseases, and 26,000
genes with genotyped variants [4].
We systematically genotyped 85 VIP variants selected
from PharmGKB VIP in 100 Tajiks from Xinjiang [6]. We
compared genotype frequencies and haplotype constructionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(JPT), Utah Residents with Northern and Western
European Ancestry (CEU), and Yorubia in Ibadan,
Nigeria (YRI). Our goals were to identify differences
and determine their extent and provide a theoretical
basis for safer drug administration and better thera-
peutic treatment in the Tajik population.
Methods
Ethics statement
All participants recruited and genotyped in the present
study had at least three generations of paternal ancestry
in their ethnic group, and each subject provided written
informed consent. The Ethics Committees of Xinjiang
University and Northwest University approved the use
of human samples in this study.
Study participants
We recruited a random sample of 100 healthy, unrelated
Tajiks (50 males and 50 females) from Tashkurgan Tajik
Autonomous County between July and October 2010
using detailed recruitment and exclusion criteria. All of
the chosen subjects were Tajik Chinese living in the
Xinjiang Uygur Autonomous Region.
Polymerase chain reaction (PCR) and DNA sequencing
We successfully genotyped 85 VIP variants in 37 phar-
macogenomic genes in 100 participants. Genomic DNA
from whole blood was isolated using the GoldMag®
nanoparticles method according to the manufacturer’s
protocol, and DNA concentration was measured by spec-
trometry (DU530 UV/VIS spectrophotometer, Beckman
Instruments, Fullerton, CA, USA). We designed primers
for amplification and extension reactions using Sequenom
MassARRAY Assay Design 3.0 Software [6] and used a
Sequenom MassARRAY RS1000 to genotype the single
nucleotide polymorphisms (SNPs) using the protocol
recommended by the manufacturer. Sequenom Typer
4.0 Software was used for data management and ana-
lysis [6,7].
Data analysis
Statistical analyses were performed using Microsoft
Excel (Redmond, WA, USA) and SPSS 16.0 statistical
package (SPSS, Chicago, IL, USA). All p values in this
study were two-sided, and p ≤ 0.005 after Bonferroni
correction was considered the statistical significance
threshold [8]. We calculated and compared the geno-
type frequencies of Tajiks and four other populations
(CHB, JPT, CEU, and YRI) using chi-squared tests [9].
We used the Haploview software package (version 4.2)
for analysis of linkage disequilibrium (LD), haplotype
construction, and genetic associations at polymorphic
loci [10-12]. Our method excluded SNPs with minorallele frequency < 0.001 for SNPs with lower frequencies
that have little power to detect LD. We also ignored SNPs
with Hardy-Weinberg equilibrium (HWE) p values < 0.001
for their small probability that their deviation from HWE
could be explained by chance. The D’ values on the square
is a measure of the LD extent for each pair of SNPs,
squares in red without D’ values indicate the two sites are
in complete LD (D’ = 1). We constructed haplotypes using
the common sites of the selected SNPs and sites down-
loaded from HapMap for the VDR gene and derived the
haplotype frequencies in all five populations.Results
We successfully sequenced 85 VIP pharmacogenomic
variant genotypes from 100 Tajiks. The PCR primers
used for the selected variants are listed in Additional file 1.
Table 1 lists the basic characteristics of the selected vari-
ants, including gene name, chromosome number and pos-
ition, and their allele frequencies in Tajiks.
Table 2 lists the genotype frequencies in Tajiks and
identifies significant variants in Tajiks compared with
the other four populations (p < 0.005), all variant data
are shown in Additional file 2. We also categorized the
genes into different families and phases related to pharma-
cogenomics, the statistically significant values are shown
in red (p < 0.05). We found that Tajiks differed from CHB,
JPT, and YRI in 30, 32, and 32 selected VIP genotypes, re-
spectively. These genes encode phase I drug metabolic en-
zymes (VCORC1, MTHFR, and CYP3A5), a phase II drug
metabolic enzymes (COMT), and transporters, channel
proteins, and receptors (e.g., ADRB1, KCNH2, and VDR,
respectively). However, the difference between Tajiks and
CEU was much smaller; just six SNP genotypes were dif-
ferent, and these were randomly distributed on genes such
as CYP2C9, which encodes a phase I enzyme. For genes
such as ADH1B and PTGS2, we observed differences be-
tween Tajiks and the other four populations.
We counted the variants in each family, excluding
those that belonged to none of the families or were not
significantly different between Tajiks and the other four
populations. The remaining 71 sites belonged to 26
genes in 12 families (Table 3). We found that the differ-
ence between Tajiks and CEU existed in only one site in
the nuclear receptor family and 0 site in adrenergic re-
ceptors family respectively. However, in the nuclear re-
ceptor family, Tajiks differed from CHB, JPT, and YRI in
66.7%, 75%, and 33.3% of selected sites, respectively. In
the adrenergic receptor family, Tajiks differed from
CHB, JPT, and YRI in 60%, 40%, and 40% of selected
sites, respectively. For genes in ATP-binding cassette
(ABC) transporters, Tajiks differed from YRI in 66.7% of
the selected sites, but there was no difference between
Tajiks and CHB, JPT, CEU.
Table 1 Basic characteristics of the selected variants
SNP ID Genes Chromosome Position Allele Allele frequencies
A B A(%) B(%)
rs1801131 MTHFR 1 11854476 C A 35.0 65.0
rs1801133 MTHFR 1 11856378 T C 19.2 80.8
rs890293 CYP2J2 1 60392494 G T 48.5 51.5
rs3918290 DPYD 1 97915614 G / 100 0
rs6025 F5 1 169519049 C A 100 0
rs20417 PTGS2 1 186650320 G C 97.0 3.0
rs689466 PTGS2 1 186650750 A G 85.4 14.7
rs4124874 UGT1A10 2 234665659 C A 42.8 57.2
rs10929302 UGT1A10 2 234665782 G A 73.5 26.5
rs4148323 UGT1A10 2 234669144 A G 3.5 96.5
rs7626962 SCN5A 3 38620907 G / 100 0
rs1805124 SCN5A 3 38645420 G A 29.0 71.0
rs6791924 SCN5A 3 38674699 G / 100 0
rs3814055 NR1I2 3 119500034 C T 58.0 42.0
rs2046934 P2RY12 3 151057642 T C 90.0 10.0
rs1065776 P2RY1 3 152553628 T C 6.1 93.9
rs701265 P2RY1 3 152554357 G A 20.0 80.0
rs975833 ADH1A 4 100201739 G C 74.2 25.8
rs2066702 ADH1B 4 100229017 C T 97.5 2.5
rs1229984 ADH1B 4 100239319 G A 70.5 29.5
rs698 ADH1C 4 100260789 A G 67.0 33.0
rs17244841 HMGCR 5 74607099 A / 100 0
rs3846662 HMGCR 5 74615328 T C 48.5 51.5
rs17238540 HMGCR 5 74619742 T / 100 0
rs1042713 ADRB2 5 148206440 G A 60.5 39.5
rs1042714 ADRB2 5 148206473 G C 34.0 66.0
rs1800888 ADRB2 5 148206885 C T 98.0 2.0
rs1142345 TPMT 6 18130918 G A 0 100
rs1800460 TPMT 6 18139228 A G 0 100
rs2066853 AHR 7 17379110 G A 82.5 17.5
rs1045642 ABCB1 7 87138645 T C 57.1 42.9
rs2032582 ABCB1 7 87160617 G T 42.7 57.3
rs2032582 ABCB1 7 87160617 G A 86.4 13.6
rs2032582 ABCB1 7 87160617 T A 92.7 7.4
rs1128503 ABCB1 7 87179601 T C 58.1 41.9
rs10264272 CYP3A5 7 99262835 C / 100 0
rs776746 CYP3A5 7 99270539 G A 89.5 10.5
rs4986913 CYP3A4 7 99358459 C T 99.0 1.0
rs4986910 CYP3A4 7 99358524 T / 100 0
rs4986909 CYP3A4 7 99359670 C / 100 0
rs12721634 CYP3A4 7 99381661 T / 100 0
rs2740574 CYP3A4 7 99382096 A G 98.5 1.5
rs3815459 KCNH2 7 150644394 A G 40.5 59.5
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Table 1 Basic characteristics of the selected variants (Continued)
rs36210421 KCNH2 7 150644428 G T 99.0 1.0
rs12720441 KCNH2 7 150647304 C / 100 0
rs3807375 KCNH2 7 150667210 A G 43.0 57.0
rs4986893 CYP2C19 10 96540410 G / 100 0
rs4244285 CYP2C19 10 96541616 G A 92.5 7.5
rs1799853 CYP2C9 10 96702047 C T 100 0
rs1801252 ADRB1 10 115804036 G A 20.2 79.8
rs1801253 ADRB1 10 115805055 C G 79.8 20.2
rs5219 KCNJ11 11 17409572 C T 56.1 43.9
rs1695 GSTP1 11 67352689 A G 77.0 23.0
rs1138272 GSTP1 11 67353579 T C 9.0 91.0
rs1800497 DRD2 11 113270828 T C 17.9 82.1
rs6277 DRD2 11 113283459 G A 61.5 38.5
rs4149056 SLCO1B1 12 21331549 T C 90.5 9.5
rs7975232 VDR 12 48238837 C A 49.0 51.0
rs1544410 VDR 12 48239835 G A 66.0 34.0
rs2239185 VDR 12 48244559 T C 51.0 49.0
rs1540339 VDR 12 48257326 G A 67.2 32.8
rs2239179 VDR 12 48257766 A G 56.5 43.5
rs3782905 VDR 12 48266167 C G 70.0 30.0
rs2228570 VDR 12 48272895 T C 34.5 65.5
rs10735810 VDR 12 48272895 C T 66.5 33.5
rs11568820 VDR 12 48302545 G A 77.3 22.7
rs1801030 SULT1A2 16 28617485 A / 100 0
rs3760091 SULT1A1 16 28620800 C G 54.1 45.9
rs7294 VKORC1 16 31102321 C T 67.0 33.0
rs9934438 VKORC1 16 31104878 G A 50.5 49.5
rs28399454 CYP2A6 19 41351267 G / 100 0
rs28399444 CYP2A6 19 41354190 A / 100 0
rs1801272 CYP2A6 19 41354533 T / 100 0
rs28399433 CYP2A6 19 41356379 G T 10.5 89.5
rs3745274 CYP2B6 19 41512841 G T 64.0 36.0
rs28399499 CYP2B6 19 41518221 T / 100 0
rs3211371 CYP2B6 19 41522715 C T 50.0 50.0
rs12659 SLC19A1 21 46951555 C T 56.6 43.4
rs1051266 SLC19A1 21 46957794 G A 55.7 44.3
rs1131596 SLC19A1 21 46957915 T C 60.6 39.4
rs4680 COMT 22 19951271 A G 53.5 46.5
rs59421388 CYP2D6 22 42523610 C / 100 0
rs28371725 CYP2D6 22 42523805 G A 90.0 10.0
rs16947 CYP2D6 22 42523943 G A 74.1 25.9
rs5030656 CYP2D6 22 42524175 AAG delAAG 99.5 0.5
rs61736512 CYP2D6 22 42525134 C / 100 0
rs28371706 CYP2D6 22 42525772 C T 99.0 1.0
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Table 2 Genotype frequencies in Tajiks compared with four other populations
SNP ID Gene Category Allele Tajik genotype
frequencies
p values against four populations
(after Bonferroni correction)
Family Phase A B AA(%) AB(%) BB(%) CHB JPT CEU YRI
rs1045642 ABCB1 ABC transporters others T C 34.3 45.5 20.2 8.49E-03 3.42E-02 3.10E-01 2.17E-18
rs1128503 ABCB1 ABC transporters others T C 32.3 51.5 16.2 3.09E-02 8.73E-01 1.69E-02 3.03E-19
rs2032582 ABCB1 ABC transporters others G T 18 49.4 32.6 9.02E-01 6.07E-01 8.24E-02 -
rs975833 ADH1A alcohol dehydrogenase phase I G C 55.6 37.4 7.1 4.86E-16 3.45E-14 6.46E-01 5.79E-01
rs1229984 ADH1B alcohol dehydrogenase phase I G A 48 45 7 3.76E-12 7.23E-11 9.18E-11 1.26E-10
rs2066702 ADH1B alcohol dehydrogenase phase I C T 95 5.1 0 2.97E-01 2.97E-01 1.94E-01 1.61E-11
rs698 ADH1C alcohol dehydrogenase phase I A G 44.3 45.4 10.3 1.21E-09 3.22E-09 1.24E-02 7.40E-11
rs1801252 ADRB1 adrenergic receptors others G A 3 34.3 62.6 1.22E-05 1.52E-05 - 2.53E-06
rs1801253 ADRB1 adrenergic receptors others C G 63.6 32.3 4 6.12E-01 3.88E-01 5.87E-02 4.12E-04
rs1042713 ADRB2 adrenergic receptors others G A 36 49 15 4.49E-03 5.67E-01 7.34E-01 6.05E-02
rs1042714 ADRB2 adrenergic receptors others G C 14 40 46 1.26E-03 3.39E-05 2.70E-02 9.85E-03
rs2066853 AHR AHR others G A 69 27 4 1.18E-05 7.65E-08 6.87E-02 9.06E-08
rs4680 COMT COMT phase II A G 31 45 24 9.95E-05 1.56E-05 5.25E-01 3.15E-05
rs28399454 CYP2A6 cytochrome P450 phase I G / 100 0 0 - - 1.00E + 00 7.81E-07
rs3745274 CYP2B6 cytochrome P450 phase I G T 46 36 18 1.07E-03 2.03E-03 5.17E-02 1.50E-01
rs28399499 CYP2B6 cytochrome P450 phase I T / 100 0 0 - - - 2.04E-06
rs4244285 CYP2C19 cytochrome P450 phase I G A 85 15 0 1.00E-03 1.56E-05 4.07E-02 8.50E-02
rs1799853 CYP2C9 cytochrome P450 phase I C T 100 0 0 - - 6.25E-05 -
rs776746 CYP3A5 cytochrome P450 phase I G A 81 17 2 2.78E-05 8.74E-05 2.58E-02 1.23E-34
rs10264272 CYP3A5 cytochrome P450 phase I C / 100 0 0 1.00E + 00 1.00E + 00 - 8.95E-09
rs6277 DRD2 G-protein-coupled receptor others G A 38 47 15 7.41E-08 1.01E-07 1.98E-02 6.51E-11
rs1800497 DRD2 G-protein-coupled receptor others T C 3.1 29.6 67.4 8.59E-06 1.43E-05 7.19E-01 2.25E-06
rs1695 GSTP1 glutathione S-transferase phase II A G 59 36 5 5.70E-01 1.96E-03 2.32E-04 1.50E-03
rs1138272 GSTP1 glutathione S-transferase phase II T C 0 18 82 3.00E-03 2.00E-03 9.22E-01 2.28E-03
rs3846662 HMGCR HMGCR phase I T C 18 61 21 2.49E-01 7.26E-01 2.12E-02 2.79E-24
rs3807375 KCNH2 eag others A G 19 48 33 6.73E-07 8.34E-12 4.02E-01 1.13E-11
rs3815459 KCNH2 eag others A G 16 49 35 6.04E-06 2.69E-09 - 6.88E-01
rs1801131 MTHFR methylenetetrahydrofolate reductase phase I C A 7 56 37 9.07E-03 5.46E-04 2.32E-01 7.36E-09
rs1801133 MTHFR methylenetetrahydrofolate reductase phase I T C 4 30.3 65.7 3.13E-07 1.21E-03 1.92E-02 9.34E-03
rs3814055 NR1I2 nuclear receptor others C T 30 56 14 8.60E-03 2.15E-03 1.00E-01 1.32E-03
rs701265 P2RY1 G-protein coupled receptor others G A 4 32 64 7.61E-02 3.04E-01 9.33E-01 2.96E-25
rs2046934 P2RY12 G-protein coupled receptor others T C 82 16 2 5.69E-02 4.97E-02 4.49E-03 6.23E-03
rs20417 PTGS2 nuclear receptor others G C 97 0 3 5.43E-04 1.57E-03 3.65E-07 4.82E-17
rs689466 PTGS2 nuclear receptor others A G 73.7 23.2 3 3.68E-11 4.34E-07 7.13E-01 1.12E-01
rs1805124 SCN5A sodium channel gene others G A 9 40 51 1.23E-04 7.59E-04 7.80E-03 4.96E-01
rs6791924 SCN5A sodium channel gene others G / 100 0 0 - - - 2.00E-03
rs7626962 SCN5A sodium channel gene others G / 100 0 0 - - - 1.24E-03
rs1051266 SLC19A1 solute carrier others G A 29.9 51.6 18.6 3.65E-01 8.28E-02 8.36E-01 2.83E-06
rs4149056 SLCO1B1 solute carrier others T C 82 17 1 2.30E-01 7.68E-01 1.47E-01 2.66E-04
rs4124874 UGT1A10 UDP-glucuronosyltransferase phase II C A 14.4 56.7 28.9 1.64E-02 6.88E-02 3.31E-01 2.73E-23
rs4148323 UGT1A10 UDP-glucuronosyltransferase phase II A G 0 7 93 7.23E-08 3.22E-03 9.00E-02 9.00E-02
rs10929302 UGT1A10 UDP-glucuronosyltransferase phase II G A 53 41 6 2.58E-03 3.31E-03 9.38E-01 4.91E-02
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Table 2 Genotype frequencies in Tajiks compared with four other populations (Continued)
rs1540339 VDR nuclear receptor others G A 47.5 39.4 13.1 1.60E-10 1.42E-11 7.78E-01 1.80E-02
rs1544410 VDR nuclear receptor others G A 40 52 8 3.05E-12 2.03E-06 1.75E-02 2.50E-01
rs2239179 VDR nuclear receptor others A G 31 51 18 4.01E-04 6.14E-05 3.63E-02 8.58E-03
rs2239185 VDR nuclear receptor others T C 22 58 20 2.86E-04 1.55E-01 - 4.37E-01
rs3782905 VDR nuclear receptor others C G 46 48 6 1.20E-01 6.72E-04 3.92E-01 7.74E-02
rs7975232 VDR nuclear receptor others C A 20 58 22 9.30E-05 2.13E-03 1.92E-02 2.44E-02
rs10735810 VDR nuclear receptor others C T 48.4 36.3 15.4 8.17E-02 8.74E-01 2.72E-01 4.64E-03
rs11568820 VDR nuclear receptor others G A 60.6 33.3 6.1 1.12E-04 4.25E-05 6.86E-01 8.35E-38
rs7294 VKORC1 VKORC1 phase I C T 44 46 10 8.00E-10 1.09E-06 7.69E-01 1.59E-04
rs9934438 VKORC1 VKORC1 phase I G A 26 49 25 1.29E-17 4.64E-14 1.01E-01 9.39E-25
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blocks and haplotypes. Using the common sites of our
study and those from HapMap in the VDR gene, we
identified two LD blocks in Tajiks, JPT, and CEU and
one LD block in CHB and YRI (Figure 1). The block
identified in all five populations spans 0.4 kb and con-
sists of two complete LD markers (rs1540339 and
rs2239179) with a D’ value equal to 1. The block identi-
fied in Tajiks, JPT, and CEU spans 0.9 kb and also con-
sists of two complete LD markers (rs7975232 and
rs1544410) with a D’ value equal to 1.
Haplotype analysis results are shown in Figure 2. For the
common block comprised of rs1540339 and rs2239179,
three kinds of haplotypes were identified in all five popula-
tions, but they differed in frequency. Three colors of bars
indicate the three kinds of haplotypes. The highest and
lowest frequencies of haplotype “AA” were found in JPT
(73.8%) and YRI (20.0%). The highest and lowest frequen-
cies of haplotype “GG” were observed in CEU (47.0%) and
JPT (22.1%). The highest and lowest frequencies of haplo-









G-protein coupled receptor 5
Methylenetetrahydrofolate reductase 2
Nuclear receptor 12
Sodium channel gene 3
Solute carrier 4
UDP-glucuronosyltransferase 3haplotype constitutions and frequencies show that there
are relatively minimal differences between Tajik and CEU,
CHB, and JPT, whereas the differences between YRI and
the other four populations seem obvious. These findings
are in accordance with the results shown in Table 3.
Discussion
With the rapid development of pharmacogenetics, serious
attention has been given to interethnic and interracial dif-
ferences in drug responses [13]. Here, we genotyped 85
variants related to pharmacogenomics in the Tajik ethnic
group for the first time and compared the results with
other ethnic populations around the world. We found that
30, 32, 32, and 6 VIP variants differed from CHB, JPT,
YRI, and CEU respectively (p < 0.005). These findings cor-
roborate the current opinion that polymorphisms with
varying frequencies occur among different populations.
Vitamin D receptor (VDR) is a gene whose function
has been widely reported. Epithelial cells convert the pri-
mary circulating form of vitamin D to its active form,
which binds VDR to regulate a variety of genes that keepSignificant variants, n (%)
CHB JPT CEU YRI
3 (60.0) 2 (40.0) 0 (0) 2 (40.0)
3 (75.0) 3 (75.0) 1 (25.0) 3 (75.0)
0 (0) 0 (0) 0 (0) 2 (66.7)
3 (24.9) 3 (24.9) 1 (8.3) 4 (16.7)
2 (50.0) 2 (50.0) 0 (0) 1 (25.0)
1 (50.0) 2 (100) 1 (50.0) 2 (100)
2 (40.0) 2 (40.0) 1 (20.0) 3 (60.0)
1 (50.0) 2 (100.0) 0 (0) 1 (50.0)
8 (66.7) 9 (75.0) 1 (8.3)0) 4 (33.3)
1 (33.3) 1 (33.3) 0 (0) 2 (66.7)
0 (0) 0 (0) 0 (0) 2 (50.0)
2 (33.7) 2 (66.7) 0 (0) 1 (33.3)
Figure 1 Linkage disequilibrium (LD) analysis of VDR in five populations. LD is displayed by standard color schemes, with bright red for
very strong LD (LOD > 2, D’ = 1), light red (LOD > 2, D’ < 1) and blue (LOD < 2, D’ = 1) for intermediate LD, and white (LOD < 2, D’ < 1) for no LD.
A. Tajiks, B. CHB, C. JPT, D. CEU, E. YRI.
Zhang et al. BMC Genetics 2014, 15:102 Page 7 of 9
http://www.biomedcentral.com/1471-2156/15/102cellular proliferation and differentiation within normal
ranges to prevent malignant transformation [14]. That is
to say, the active form of vitamin D can induce apoptosis
and prevent angiogenesis by binding VDR, which re-
duces the survival potential of malignant cells. Studies
have demonstrated that rs10735810 and rs1544410 SNPs
in VDR might modulate the risk of breast, skin, and
prostate cancers, as well as other forms [15,16]. An
Italian study reported that GA and AA rs1544410 geno-
types were associated with decreased cutaneous malig-
nant melanoma (CMM) risk (odds ratio = 0.78 and 0.75,
respectively) compared with the GG genotype [16]. A
study in Japan found that head and neck squamous cell
carcinoma patients with the TT rs10735810 genotype
was associated with poor progression-free survival
compared with CC or CT genotype patients (log-rank
test, p = 0.0004; adjusted hazard ratio, 3.03; 95% confi-
dence interval, 1.62 to 5.67; p = 0.001), and the A-T-G
(rs11568820-rs10735810-rs7976091) haplotype showed
a significant association with a higher progression rate
(p = 0.02). [14] We found that the GA and AA genotypeFigure 2 Haplotype analysis results of rs1540339 and rs2239179 in Vfrequencies of rs1544410 in Tajiks were as much as
52% and 8% respectively, which is different from those
in CHB and JPT (data not shown), suggesting that
Tajiks may have decreased susceptibility to CMM.
The gene alcohol dehydrogenase 1B (ADH1B) pro-
duces a key protein for alcohol metabolism that deter-
mines blood acetaldehyde concentrations after drinking
[17]. This member of the alcohol dehydrogenase family
also metabolizes a wide variety of substrates besides etha-
nol, including retinol, other aliphatic alcohols, hydroxys-
teroids, and lipid peroxidation products. The minor allele
“A” of rs1229984 encodes a super-active allozyme that is
reportedly associated with lower rates of alcohol depend-
ence in numerous association studies, and its fre-
quency varies widely across different populations. It is
69% (19-91%) in normal Asian normal populations,
5.5% (1-43%) in normal European populations, and just
3% (2-7%) in normal Mexican populations [18]. Other
studies have shown that rs1229984 may influence alco-
hol consumption behavior and is associated with upper
aerodigestive (UADT) cancers [19-24]. A genome-wideDR.
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was associated with decreased UADT risk (p = 7 × 10−9)
[19]. The data in our study is in accordance with previous
findings; we found that the “A” allele frequency of
rs1544410 in Tajiks was 29.5%, which was significantly dif-
ferent (p < 0.05) from 76.67%, 73.86%, 0%, and 0% in CHB,
JPT, CEU, and YRI respectively, suggesting that Tajiks
have an intermediate susceptibility to UADT cancer.
The catechol-o-methyltransferase gene (COMT) is re-
sponsible for eliminating dopamine from the synaptic
cleft in the prefrontal cortex (PFC) [25]. Variations in
the COMT gene exert complex effects on susceptibility
to depression through various intermediate phenotypes,
such as impulsivity and executive function [26]. The com-
mon functional COMT polymorphism rs4680 has been
shown to affect enzyme activity and, consequently, intra-
synaptic dopamine content. The “G” allele is associated
with 40% higher enzymatic activity in the human brain
compared to the “A” allele, leading to more efficient elim-
ination of dopamine from the synaptic cleft; therefore, the
GG genotype is associated with reduced synaptic dopa-
mine in the PFC, and in turn, more active striatal dopa-
mine neurotransmission [25,27-29]. A study in northern
Italy reported an association between the GG genotype
and the risks of Alzheimer’s disease (AD) and its precur-
sor, mild cognitive impairment (MCI) [30]. The GG geno-
type frequency in our study was just 24% in Tajiks,
compared with 51.2%, 50%, and 46% in CHB, JPT, and
YRI respectively (p < 0.05). This suggests that Tajiks may
be less vulnerable to diseases related to dopamine content,
including AD and MCI.
Our study also found significant differences in geno-
type frequencies between Tajiks and other populations
in genes such as DRD2 and F5. Polymorphisms in these
genes have been shown to be associated with dyskinesia
induced by levodopa therapy in Parkinson’s disease pa-
tients and coronary artery disease, respectively [31,32].
The Tajiks speak a western Indo-Iranian language and
their presence in China dates to the 10th-century Muslim
invasion, suggesting they are descendants of eastern Indo-
Iranian speakers [33]. This may explain the smaller differ-
ences between Tajiks and CEU compared to other three
populations we investigated.
However, intrinsic limitations still exist in our study.
Our sample size is relatively not big enough, thus further
investigation related to pharmacogenomics gene poly-
morphisms in a larger Tajik population is necessary to
ascertain the results obtained in the current study.
Conclusions
These results provide the first pharmacogenomics infor-
mation in Tajiks and illustrate the difference of selected
genes between Tajiks and four other populations. Present-
day China is a nation with 56 distinct ethnic groups. Ourstudy provides a theoretical basis for safer drug adminis-
tration and better therapeutic treatments in this unique
population, and may also be applied in the diagnosis and
prognosis of specific diseases in Tajiks.
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